PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17192125-6	2006	In the EUTOPIA (EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis) trial, olmesartan medoxomil significantly reduced serum levels of high-sensitivity C-reactive protein, high-sensitivity TNFalpha, IL-6, and MCP-1, all of which are involved in promoting atherosclerosis.	olmesartan	105-115	interleukin 6	Homo sapiens	228-232	
34853573-10	2021	Olmesartan significantly decreased ASDAS, BASDAI, BASFI, ESR, CRP, IL-6, TNF-alpha, and SCORE as compared with placebo.	olmesartan	0-10	interleukin 6	Homo sapiens	67-71	
32248168-7	2020	The level of IL-6 has significantly decreased, both with the administration of olmesartan (2.7 times) and telmisartan (2.6 times) (p<0.01).	olmesartan	79-89	interleukin 6	Homo sapiens	13-17